| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 25.70 mm | 25.70 mm | 25.70 mm | 25.70 mm | 25.70 mm | 25.70 mm |
| Cash burn (monthly) | 2.87 mm | 2.84 mm | 2.45 mm | 3.51 mm | 2.87 mm | 3.63 mm |
| Cash used (since last report) | 74.76 mm | 74.11 mm | 63.86 mm | 91.44 mm | 74.75 mm | 94.78 mm |
| Cash remaining | -49.06 mm | -48.41 mm | -38.16 mm | -65.74 mm | -49.05 mm | -69.08 mm |
| Runway (months of cash) | -17.1 | -17.0 | -15.6 | -18.8 | -17.1 | -19.0 |
| 13F holders | Current |
|---|---|
| Total holders | 2 |
| Opened positions | 1 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 488.39 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 488.37 k | $0.00 |
| Ameriflex | 18.00 | $0.00 |
| Proequities | 0.00 | $0.00 |
